Concise Prescribing Info
Trazodone HCl
Symptomatic relief of depressive illness.
Dosage/Direction for Use
Adult Initially 150-200 mg daily in 2 or 3 divided doses; may be increased by increments of 50 mg, usually up to 300 mg daily in divided doses. Once an adequate response has been achieved, dose may be gradually reduced, w/ adjustment depending on therapeutic response.
Should be taken with food: Take shortly after a meal or a light snack.
Special Precautions
Potential association w/ behavioral & emotional changes, including self-harm. Monitor patients for emergence of suicidal ideation or behaviour. Discontinuation symptoms; gradual reduction of dose is recommended. Not recommended for use during initial recovery phase of MI. Associated w/ QTc interval prolongation. May be arrhythmogenic. Rare cases of priapism. May cause hypotension including orthostatic hypotension & syncope. Increased risk of bleeding events. Risk of serotonin syndrome or neuroleptic malignant syndrome-like events. Hyponatremia. Discontinue if WBC or absolute neutrophil count falls below normal. Patients w/ cardiac disease; history of seizures or w/ unstable epilepsy; history of mania/hypomania. Concomitant use w/ CYP3A4 inhibitors/inducers; alcohol, barbiturates & other CNS depressants. May impair mental or physical abilities required for performance of potentially hazardous tasks eg, operating an automobile or machinery. Patients w/ hepatic or renal impairment. Pregnancy & lactation. Risk of neonatal complications during use in late 3rd trimester of pregnancy. Not indicated for use in childn <18 yr. Elderly >65 yr.
Adverse Reactions
Headache, drowsiness, sedation, dry mouth, dizziness, nausea, fatigue, diarrhea, constipation, back pain, blurred vision.
Drug Interactions
Increased plasma conc w/ CYP3A4 inhibitors (eg, ketoconazole, itraconazole, voriconazole, clarithromycin, erythromycin, atazanavir, indinavir, nelfinavir, ritonavir, saquinavir, amiodarone, grapefruit juice). Decreased plasma conc w/ CYP3A4 inducer eg, carbamazepine. Additive effect on QTc w/ other QTc-prolonging drugs or drugs that can disrupt electrolyte levels. Increased serum levels of digoxin or phenytoin. Increased risk of serotonin syndrome w/ MAOIs or other serotonergic drugs eg, tryptophan, triptans, SSRIs, lithium, fentanyl, tramadol, or St. John's Wort. Increased risk of bleeding w/ NSAIDs, aspirin or other drugs that affect coagulation or bleeding. Increased/decreased prothrombin time w/ warfarin. Enhanced response to alcohol, barbiturates & other CNS depressants. General anesth should be discontinued for as long as clinically feasible prior to elective surgery.
MIMS Class
ATC Classification
N06AX05 - trazodone ; Belongs to the class of other antidepressants.
pms-Trazodone tab 100 mg
pms-Trazodone tab 50 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in